Prescription Drug Advertising and Drug Utilization: The Role of Medicare Part D

Overview

Journal J Public Econ

Date 2023 Jun 5

PMID 37275770

Authors

Abby Alpert

Darius Lakdawalla

Neeraj Sood

Affiliations

Soon will be listed here.

Abstract

This paper examines how direct-to-consumer advertising (DTCA) for prescription drugs influences utilization by exploiting a large and plausibly exogenous shock to DTCA driven by the introduction of Medicare Part D. Part D led to larger increases in advertising in geographic areas with higher concentrations of Medicare beneficiaries. We examine the impact of this differential increase in advertising on non-elderly individuals to isolate advertising effects from the direct effects of Part D. We find that exposure to advertising led to large increases in treatment initiation and improved medication adherence. Advertising also had sizeable positive spillover effects on non-advertised generic drugs. Our results imply significant spillovers from Medicare Part D on the under-65 population and an important role for non-price factors in influencing prescription drug utilization.

Citing Articles

Pathways for non-manufacturers to drive generic drug repurposing for cancer in the U.S.

Crittenden D, Gallagher R, Milans Del Bosch F, Fox D, Kleiman L Front Pharmacol. 2024; 15:1419772.

PMID: 39444616 PMC: 11496753. DOI: 10.3389/fphar.2024.1419772.

Physicians Treating Alzheimer's Disease Patients Should Be Aware that Televised Direct-to-Consumer Advertising Links More Strongly to Drug Utilization in Older Patients.

Feldman R J Alzheimers Dis. 2021; 81(3):1169-1179.

PMID: 33843688 PMC: 8293633. DOI: 10.3233/JAD-210294.

How increasing medical access to opioids contributes to the opioid epidemic: Evidence from Medicare Part D.

Powell D, Pacula R, Taylor E J Health Econ. 2020; 71:102286.

PMID: 32193022 PMC: 7231644. DOI: 10.1016/j.jhealeco.2019.102286.

Vitamin panacea: Is advertising fueling demand for products with uncertain scientific benefit?.

Eisenberg M, Avery R, Cantor J J Health Econ. 2017; 55:30-44.

PMID: 28743536 PMC: 5599169. DOI: 10.1016/j.jhealeco.2017.06.003.

References

Goldman D, Joyce G, Escarce J, Pace J, Solomon M, Laouri M . Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004; 291(19):2344-50. DOI: 10.1001/jama.291.19.2344. View

Pandya A, Sy S, Cho S, Weinstein M, Gaziano T . Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease. JAMA. 2015; 314(2):142-50. PMC: 4797634. DOI: 10.1001/jama.2015.6822. View

Majumdar S, Gurwitz J, Soumerai S . Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med. 2000; 14(12):711-7. PMC: 1496865. DOI: 10.1046/j.1525-1497.1999.02229.x. View

Avery R, Eisenberg M, Simon K . The impact of direct-to-consumer television and magazine advertising on antidepressant use. J Health Econ. 2012; 31(5):705-18. DOI: 10.1016/j.jhealeco.2012.05.002. View

Zhang Y, Donohue J, Lave J, Gellad W . The impact of Medicare Part D on medication treatment of hypertension. Health Serv Res. 2010; 46(1 Pt 1):185-98. PMC: 3034269. DOI: 10.1111/j.1475-6773.2010.01183.x. View

Donohue J, Berndt E, Rosenthal M, Epstein A, Frank R . Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression. Med Care. 2004; 42(12):1176-85. DOI: 10.1097/00005650-200412000-00004. View

Baigent C, Keech A, Kearney P, Blackwell L, Buck G, Pollicino C . Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366(9493):1267-78. DOI: 10.1016/S0140-6736(05)67394-1. View

Ketcham J, Simon K . Medicare Part D's effects on elderly patients' drug costs and utilization. Am J Manag Care. 2008; 14(11 Suppl):SP14-22. View

Berndt E, Bui L, Reiley D, Urban G . Information, marketing, and pricing in the U.S. antiulcer drug market. Am Econ Rev. 1995; 85(2):100-5. View

10.

Schwartz L, Woloshin S . Medical Marketing in the United States, 1997-2016. JAMA. 2019; 321(1):80-96. DOI: 10.1001/jama.2018.19320. View

11.

Goldman D, Joyce G, Zheng Y . Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007; 298(1):61-9. PMC: 6375697. DOI: 10.1001/jama.298.1.61. View

12.

Hirschfeld R, Keller M, Panico S, Arons B, Barlow D, Davidoff F . The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA. 1997; 277(4):333-40. View

13.

Bradford W, Kleit A, Nietert P, Steyer T, McIlwain T, Ornstein S . How direct-to-consumer television advertising for osteoarthritis drugs affects physicians' prescribing behavior. Health Aff (Millwood). 2006; 25(5):1371-7. DOI: 10.1377/hlthaff.25.5.1371. View

14.

Lichtenberg F, Sun S . The impact of Medicare Part D on prescription drug use by the elderly. Health Aff (Millwood). 2007; 26(6):1735-44. DOI: 10.1377/hlthaff.26.6.1735. View

15.

Alpert A . The anticipatory effects of Medicare Part D on drug utilization. J Health Econ. 2016; 49:28-45. PMC: 10621617. DOI: 10.1016/j.jhealeco.2016.06.004. View

16.

Yin W, Basu A, Zhang J, Rabbani A, Meltzer D, Alexander G . The effect of the Medicare Part D prescription benefit on drug utilization and expenditures. Ann Intern Med. 2008; 148(3):169-77. DOI: 10.7326/0003-4819-148-3-200802050-00200. View

17.

Blume-Kohout M, Sood N . Market Size and Innovation: Effects of Medicare Part D on Pharmaceutical Research and Development. J Public Econ. 2013; 97:327-336. PMC: 3711884. DOI: 10.1016/j.jpubeco.2012.10.003. View

18.

Duggan M, Scott Morton F . The Effect of Medicare Part D on Pharmaceutical Prices and Utilization. Am Econ Rev. 2018; 100(1):590-607. DOI: 10.1257/aer.100.1.590. View

19.

Lakdawalla D, Yin W . Insurers' Negotiating Leverage and the External Effects of Medicare Part D. Rev Econ Stat. 2015; 97(2):314-331. PMC: 4414344. DOI: 10.1162/REST_a_00463. View

20.

Andrade S, Kahler K, Frech F, Chan K . Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006; 15(8):565-74. DOI: 10.1002/pds.1230. View